Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company is focusing on the development of chimeric antigen receptor (CAR)-based immunotherapies using autologous T-cells. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137. The company is also developing intracellular targeting antibodies comprising STAT3, Mutant KRAS, MYC, p53, and TAU to modulate the evolution of cancer, inflammation, autoimmune diseases, diabetes, central nervous system diseases, cardiovascular diseases, and viral infections; and oncolytic viruses that infect and selectively multiply in and destroy tumor cells without damaging healthy tissue. In addition, it offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company has a licensing agreement with Mabtech Limited to develop and commercialize multiple prespecified biosimilar and biobetter antibodies from based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRNE
Previous Symbol
CUSIPN/A
Phone858-203-4100
Debt
Debt-to-Equity Ratio0.65
Current Ratio1.76
Quick Ratio1.76
Price-To-Earnings
Trailing P/E Ratio25.31
Forward P/E Ratio-2.02
P/E GrowthN/A
Sales & Book Value
Annual Sales$151.86 million
Price / Sales2.64
Cash Flow$0.1784 per share
Price / Cash18.39
Book Value$2.50 per share
Price / Book1.31
Profitability
EPS (Most Recent Fiscal Year)$0.13
Net Income$9.13 million
Net Margins-303.79%
Return on Equity-46.62%
Return on Assets-22.72%
Miscellaneous
Employees162
Outstanding Shares122,270,000
Market Cap$453.64 million
OptionableOptionable
Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions
What is Sorrento Therapeutics' stock symbol?
Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."
When is Sorrento Therapeutics' next earnings date?
What price target have analysts set for SRNE?
3 equities research analysts have issued 1-year price targets for Sorrento Therapeutics' shares. Their predictions range from $10.00 to $40.00. On average, they expect Sorrento Therapeutics' share price to reach $21.4167 in the next twelve months. This suggests a possible upside of 552.9% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.
What is the consensus analysts' recommendation for Sorrento Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.
Has Sorrento Therapeutics been receiving favorable news coverage?
Press coverage about SRNE stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Sorrento Therapeutics' key competitors?
Some companies that are related to Sorrento Therapeutics include Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI), Dyadic International (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), US Stem Cell (USRM), Protalex (PRTX), Tenax Therapeutics (TENX), Geovax Labs (GOVX) and ALGAE TEC LTD/S (ALGXY).
Who are Sorrento Therapeutics' key executives?
Sorrento Therapeutics' management team includes the folowing people:
- Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 54)
- Mr. George K. Ng, Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)
- Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 68)
- Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 50)
- Dr. Alexis Nahama, VP of Corp. Devel.
Who are Sorrento Therapeutics' major shareholders?
Sorrento Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.40%), Bank of New York Mellon Corp (0.34%), FMR LLC (0.31%), Vident Investment Advisory LLC (0.27%), AXA (0.25%) and AQR Capital Management LLC (0.23%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde, Pacific Medtech (Bvi) Ltd Asia and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.
Which institutional investors are selling Sorrento Therapeutics stock?
SRNE stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Renaissance Technologies LLC, Virtus ETF Advisers LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., First Republic Investment Management Inc. and Vident Investment Advisory LLC. Company insiders that have sold Sorrento Therapeutics company stock in the last year include Abg Management Ltd and Pacific Medtech (Bvi) Ltd Asia. View Insider Buying and Selling for Sorrento Therapeutics.
Which institutional investors are buying Sorrento Therapeutics stock?
SRNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Man Group plc, AXA, Russell Investments Group Ltd., AQR Capital Management LLC, Bank of New York Mellon Corp and TCW Group Inc.. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, George K Ng, Henry Ji, Jaisim Shah, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.
How do I buy shares of Sorrento Therapeutics?
Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sorrento Therapeutics' stock price today?
One share of SRNE stock can currently be purchased for approximately $3.28.
How big of a company is Sorrento Therapeutics?
Sorrento Therapeutics has a market capitalization of $453.64 million and generates $151.86 million in revenue each year. The biopharmaceutical company earns $9.13 million in net income (profit) each year or $0.13 on an earnings per share basis. Sorrento Therapeutics employs 162 workers across the globe.
What is Sorrento Therapeutics' official website?
How can I contact Sorrento Therapeutics?
Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]
MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
